Skip to main content
Article thumbnail
Location of Repository

Antigenic Fingerprinting of H5N1 Avian Influenza Using Convalescent Sera and Monoclonal Antibodies Reveals Potential Vaccine and Diagnostic Targets

By Surender Khurana, Amorsolo L. Suguitan, Yonaira Rivera, Cameron P. Simmons, Antonio Lanzavecchia, Federica Sallusto, Jody Manischewitz, Lisa R. King, Kanta Subbarao and Hana Golding

Abstract

Using whole-genome-fragment phage display libraries, Hana Golding and colleagues identify the viral epitopes recognized by serum antibodies in humans who have recovered from infection with H5N1 avian influenza

Topics: Research Article
Publisher: Public Library of Science
OAI identifier: oai:pubmedcentral.nih.gov:2661249
Provided by: PubMed Central
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • http://www.pubmedcentral.nih.g... (external link)
  • Suggested articles

    Citations

    1. (2007). A single mutation in the PB1-F2 of H5N1 (HK/97) and 1918 influenza A viruses contributes to increased virulence.
    2. (1999). A universal influenza A vaccine based on the extracellular domain of the M2 protein.
    3. (1993). Antibody response to the M2 protein of influenza A virus expressed in insect cells.
    4. (2008). Characterizations of four monoclonal antibodies against M2 protein ectodomain of influenza A virus.
    5. (2007). Comparison of neutralising antibody assays for detection of antibody to influenza A/H3N2 viruses: an international collaborative study.
    6. (2007). Cross-reactive neuraminidase antibodies afford partial protection against H5N1 in mice and are present in unexposed humans. PLoS Med 4: e59. doi:10.1371/ journal.pmed.0040059.
    7. (2004). Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine.
    8. (1999). Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays.
    9. (2007). Epitope mapping of the hemagglutinin molecule of a highly pathogenic H5N1 influenza virus by using monoclonal antibodies.
    10. (2006). Evolution and adaptation of H5N1 influenza virus in avian and human hosts
    11. (2006). Fatal outcome of human influenza A (H5N1) is associated with high viral load and hypercytokinemia.
    12. (2008). Heterosubtypic neutralizing monoclonal antibodies cross-protective against
    13. (2006). Human immunodeficiency virus (HIV) vaccine trials: a novel assay for differential diagnosis of HIV infections in the face of vaccine-generated antibodies.
    14. (2008). Human infection with highly pathogenic H5N1 influenza virus.
    15. (2009). Identification of a linear peptide recognized by monoclonal antibody 2D7 capable of generating CCR5-specific antibodies with human immunodeficiency virus-neutralizing activity.
    16. (1982). Immunogenic structure of the influenza virus hemagglutinin.
    17. (2006). Influenza A virus PB1-F2 protein contributes to viral pathogenesis in mice.
    18. Klimov A (2008) HA2-specific monoclonal antibodies as tools for differential recognition of influenza A virus antigenic subtypes.
    19. (2007). Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1.
    20. (2006). Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?
    21. (2006). Novel approach for differential diagnosis of HIV infections in the face of vaccinegenerated antibodies: utility for detection of diverse HIV-1 subtypes.
    22. (2005). Oseltamivir resistance during treatment of influenza A (H5N1) infection.
    23. (1990). Passively transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in mice.
    24. Please access these Web sites via the online version of this summary at http://dx.doi.org/10.
    25. (2004). Preclinical study of influenza virus A M2 peptide conjugate vaccines in mice, ferrets, and rhesus monkeys.
    26. (2007). Prophylactic and therapeutic efficacy of human monoclonal antibodies against H5N1 influenza.
    27. (2006). Prospects for universal influenza virus vaccine.
    28. (2007). Scientific barriers to developing vaccines against avian influenza viruses.
    29. (2007). Sette A
    30. (1991). Structural assignment of novel and immunodominant antigenic sites in the neutralizing antibody response of CBA/Ca mice to influenza hemagglutinin.
    31. (1981). Structural identification of the antibodybinding sites of Hong Kong influenza haemagglutinin and their involvement in antigenic variation.
    32. (2002). Structure of antigenic sites on the haemagglutinin molecule of H5 avian influenza virus and phenotypic variation of escape mutants.
    33. (1995). Structure of influenza virus haemagglutinin complexed with a neutralizing antibody.
    34. (1981). Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.
    35. (2006). The structure of H5N1 avian influenza neuraminidase suggests new opportunities for drug design.
    36. (2007). Treatment with convalescent plasma for influenza A (H5N1) infection.

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.